News from inovio pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 18, 2014, 06:00 ET

Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in...

Dec 17, 2014, 08:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In...

Dec 15, 2014, 08:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has been added to the NASDAQ Biotechnology Index (NBI). The addition to the...

Nov 24, 2014, 06:00 ET

Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, will be joined...

Nov 20, 2014, 08:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals Melanoma DNA Immunotherapy Inhibits Tumor Growth and Increases Survival in Preclinical Study

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and...

Nov 17, 2014, 03:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license...

Nov 11, 2014, 06:00 ET
Inovio Pharmaceuticals.

Inovio to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the...

Nov 10, 2014, 06:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals Reports 2014 Third Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended September 30, 2014. Total revenue was $1.8...

Nov 04, 2014, 06:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its third quarter...

Oct 21, 2014, 06:00 ET
Inovio Pharmaceuticals.

Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for...

Sep 30, 2014, 07:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals Appoints Vice President of Commercial Development

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position...

Sep 24, 2014, 06:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a...

Sep 22, 2014, 08:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has initiated a phase I clinical trial in patients with aerodigestive cancers....

Sep 18, 2014, 06:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio to Present at Upcoming Investor Conferences

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today CEO Dr. J. Joseph Kim will be presenting at two upcoming investor conferences in...

Sep 15, 2014, 08:59 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange

 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has met the stringent listing criteria for the NASDAQ Global Select Market...

Sep 04, 2014, 09:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals to List on NASDAQ

 Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has met the listing criteria for the NASDAQ Global Select Market and will...

Sep 03, 2014, 08:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Inovio will present at the upcoming Rodman and Renshaw Investment Conference in...

Aug 11, 2014, 08:30 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals Reports 2014 Second Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million...

Aug 01, 2014, 08:00 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial...

Jul 23, 2014, 09:15 ET
Inovio Pharmaceuticals.  (PRNewsFoto/Inovio Pharmaceuticals, Inc.)

Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II...